Humana Stock Rises After Medicare Advantage Plan Earns Higher Star Rating

A rating upgrade to one of Humana's largest Medicare Advantage plans triggers eligibility for federal bonus payments in 2027, shifting a key revenue variable for the insurer heading into the next...

Humana Inc. (HUM) shares rose on October 8, 2026, after the Centers for Medicare and Medicaid Services awarded a higher Star Rating to one of the company's major Medicare Advantage plans, making that plan eligible for quality bonus payments in the 2027 payment year, according to Investor's Business Daily.

The CMS Star Ratings system scores Medicare Advantage and Part D prescription drug plans on a scale of one to five stars, measuring factors including chronic disease management, customer service, and member experience. Plans that reach four stars or above qualify for bonus payments from the federal government, which are calculated as a percentage above the standard benchmark payment rate set annually by CMS.

The precise magnitude of Humana's rating change, the plan's prior star level, and the dollar value of the bonus payments it will receive in 2027 were not disclosed in the reporting available as of publication. CMS publishes full plan-level star data in its annual release; those figures would clarify the financial impact of this specific upgrade.

Humana is one of the largest Medicare Advantage insurers in the United States. The company's 2025 annual report, filed with the Securities and Exchange Commission, identified Medicare Advantage as its primary business segment and the principal source of its premium revenue. Changes to star ratings therefore carry direct implications for the company's per-member reimbursement rates from the federal government.

The Medicare Advantage program has grown steadily as a share of total Medicare enrollment. CMS data published in 2025 showed that more than half of all Medicare beneficiaries were enrolled in Medicare Advantage plans, making the program's payment structure a significant and recurring factor in the financial results of major insurers including Humana, UnitedHealth Group, and CVS Health's Aetna division.

For Humana specifically, star ratings have been a source of financial volatility in recent years. The company disclosed in prior SEC filings that a decline in star ratings for certain plans reduced its bonus payment eligibility and contributed to margin pressure. A reversal of that trend, if confirmed at scale, would represent a change in that financial dynamic.

Bonus payments tied to star ratings are not paid in the same year the rating is awarded. Under CMS rules, a rating assigned in one year determines bonus eligibility for plans sold in the following year, with payments flowing in the year after that. The 2026 star ratings released in October 2026 therefore affect payment rates for the 2027 contract year.

The size of the quality bonus payment per enrollee depends on the county-level benchmark payment and the plan's star level. CMS sets those benchmarks annually through its rate notice process. The 2027 rate notice, which would govern the payment amounts applicable to this rating upgrade, was published earlier in 2026 and is available in the CMS Rate Announcement.

Humana is scheduled to report its third-quarter 2026 earnings at a date not yet confirmed in available public records as of October 8, 2026. That earnings release and any accompanying guidance update would be the next scheduled disclosure in which management could quantify the projected revenue effect of the star rating change on 2027 financials.

Investors tracking Medicare Advantage reimbursement policy more broadly may also note that Congress has periodically considered modifications to the quality bonus payment structure as part of broader Medicare cost debates. No legislation altering the bonus payment formula had been enacted as of the publication date of this article.